Clarus Ventures, LLC

Clarus Ventures, LLC is a specialist life sciences venture-capital firm historically headquartered in the Boston, Massachusetts area, with additional presence on the U.S. West Coast. Founded in the mid‑2000s by a team including Nicholas Galakatos, Ph.D., and Michael Steinmetz, M.D., Clarus focused on building and financing innovative biotechnology, pharmaceutical, medical device, and life science tools companies. In 2018 the Clarus platform was acquired by Blackstone and became the foundation of Blackstone Life Sciences, although the Clarus Ventures, LLC entity continues to appear in SEC regulatory filings, including under CIK #0001431431. The firm’s core business has been venture and growth equity investing across the life sciences value chain. Clarus has backed companies from clinical‑stage biotechnology through commercial‑stage specialty pharma and medical technology, often structuring complex, milestone‑driven financings and asset‑backed transactions with large pharmaceutical partners. Its investor base has been predominantly institutional—pension funds, endowments, foundations, and insurance companies—accessing the strategy through closed‑end venture funds and related vehicles. Clarus Ventures, LLC files Form 13F with the U.S. Securities and Exchange Commission as an institutional investment manager. These filings capture the subset of its activity represented by long positions in U.S.‑listed securities: primarily equity stakes in portfolio companies that have gone public via IPO or reverse merger, and occasionally public follow‑on or crossover investments. The 13F reports do not reveal the extensive private holdings, structured royalty or asset financings, or derivative and credit instruments that are integral to the firm’s venture and life‑sciences financing model. On this platform, Clarus’s 13F History is organized into a quarter‑by‑quarter record of disclosed U.S.‑listed positions, giving allocators a factual lens into how the venture portfolio has transitioned from private to public markets over time.

Clarus Ventures employs a fundamental, science‑driven venture and growth equity strategy focused exclusively on life sciences. The firm targets opportunities where it believes rigorous scientific and clinical assessment, combined with deep industry relationships, can identify mispriced or underappreciated therapeutic and technology platforms. Key elements of the Clarus approach include: - Therapeutic and technology focus: Investments span biotechnology, small‑molecule and biologic pharmaceuticals, medical devices, diagnostics, and life science tools, with an emphasis on areas of clear unmet medical need and differentiated mechanisms of action. - Stage flexibility with a late‑stage bias: While capable of investing from early clinical stages onward, Clarus has often emphasized late‑stage and crossover financings—situations where substantial clinical data already exist and where capital can support pivotal trials, regulatory filings, launches, or label expansions. - Structured and asset‑backed transactions: In addition to traditional venture equity, Clarus has been known for structuring deals backed by specific assets, royalty streams, or development programs in partnership with large pharmaceutical companies. - High conviction and concentration: Portfolios are deliberately concentrated in a limited number of platform companies, each sized to be meaningful at the fund level. Capital is typically staged over time as clinical and regulatory milestones are achieved. The positions visible in Form 13F are the public‑market expression of this process. They generally include: - Legacy positions in portfolio companies that have completed an IPO or similar listing, where Clarus retains a significant equity stake. - Crossover investments in public life science companies made in the late private or pre‑IPO phase and held through the public transition. - Occasional public‑only investments in life sciences names that fit Clarus’s thematic and scientific criteria. Because venture investments are multi‑year endeavors, turnover in the 13F‑reported holdings is typically low. Positions are exited as liquidity windows open—through secondary offerings, block trades, or gradual distribution of shares to limited partners—rather than via frequent trading. Within this analytics environment, the 13F Portfolio Composition view allows allocators to dissect Clarus’s disclosed U.S.‑listed holdings by subsector (biotech, pharma, medtech), market capitalization, and issuer concentration. Coupled with a Portfolio Simulator and Backtesting Service, it is possible to construct a historical replication of the long public sleeve and study how Clarus’s life‑science stock selection has contributed to its observable capital trajectory, with the caveat that the more extensive private and structured deals sit outside the 13F dataset.

Clarus Ventures, LLC is a Boston‑based life‑sciences venture firm whose platform, now part of Blackstone Life Sciences, has been built around concentrated, high‑conviction investments in biotechnology, pharmaceuticals, medtech, and life science tools. Its Form 13F filings under CIK #0001431431 provide a focused view of the public‑equity portion of that strategy—the U.S.‑listed stakes in portfolio companies that have reached the public markets or been accessed via crossover rounds. From the 13F vantage point, Clarus’s observable characteristics include: - A sector‑specialist, venture‑style profile with heavy exposure to biotech and related life‑sciences subsectors. - High issuer concentration and pronounced event risk around clinical and regulatory milestones. - Low turnover in core holdings, reflecting multi‑year investment horizons and staged exits tied to liquidity events. Within this analytics platform, users can build a reconstructed Historical Track Record of Clarus’s reportable positions and compare the resulting capital path with broad equity and biotech benchmarks. Combining 13F Portfolio Composition analytics with downside measures such as Max Drawdown Depth and efficiency metrics like Sharpe Ratio provides a structured, data‑grounded perspective on how Clarus’s life‑sciences venture selections have behaved in the portion of the portfolio disclosed via 13F. The central analytical question for allocators is how this concentrated, event‑driven biotech and life‑sciences exposure—seen solely through Clarus Ventures’ 13F history—responds across different market and sector regimes, including drug‑pricing debates, funding booms and busts, and shifts in risk appetite, and whether that regime sensitivity aligns with the role they intend such exposure to play in a broader, multi‑manager portfolio.

The risk profile of Clarus Ventures, viewed through its 13F filings, reflects that of a concentrated, sector‑specialist venture investor operating in biotechnology and related life science industries. The reconstructed public‑equity sleeve is fully exposed to: - Clinical and regulatory event risk: Individual holdings are often tied to binary or near‑binary outcomes—clinical trial read‑outs, regulatory decisions, safety findings—which can produce large price jumps or collapses. - Sector cyclicality and sentiment: The portfolio’s heavy concentration in biotech and pharma makes it sensitive to funding conditions, drug‑pricing debates, M&A cycles, and shifts in investor appetite for risk within healthcare. - Idiosyncratic scientific risk: Even in diversified life‑science portfolios, a small number of core positions can dominate exposure, and setbacks in those names can materially shape the capital path. Given the high‑conviction nature of Clarus’s strategy, the top holdings in any given 13F period frequently account for a substantial share of reported market value. This concentration amplifies both upside and downside, as successful drug approvals or strategic transactions can significantly enhance capital compounding, while trial failures or regulatory rejections can drive deep, name‑specific drawdowns. At the same time, Clarus’s focus on later‑stage or de‑risked programs, where substantial data are available, is intended to partially mitigate early‑stage binary risk. Deep due diligence on trial design, competitive landscape, and regulatory pathways is used to improve the odds of success, though it cannot eliminate the inherent uncertainty of drug and device development. On this platform, a 13F‑based replication of Clarus’s disclosed public holdings can be evaluated using standard risk diagnostics. Measures such as Max Drawdown Depth help quantify the worst peak‑to‑trough capital declines experienced by the reconstructed sleeve over chosen horizons, while a Sharpe Ratio lens relates that variability to the excess compounding achieved versus a cash proxy. Scenario analysis and stress testing—implemented via Performance Backtests Online—can be used to explore how the observable book would likely have behaved during biotech bull markets, sector‑wide drawdowns, funding droughts, or periods of heightened regulatory scrutiny. It is important to note that this analysis covers only the long, U.S.‑listed component of Clarus’s activity. Private holdings, structured financings, royalties, and any hedging overlays are not visible in 13F data and may materially affect the total‑portfolio risk and compounding behavior at the fund level.